Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is a clinical-stage biotechnology company that is poised for potential success in the near future due to the expected initiation of its Phase 1b/2a trial for SZN-8141 in DME patients by year-end 2026 and subsequent data catalyst in 2H27. The company also received a positive ruling from the US Patent Trial and Appeal Board, solidifying its intellectual property position. With promising preclinical results and a strategic partnership with Boehringer Ingelheim, Surrozen has the potential to differentiate itself in the competitive Wnt therapeutics landscape and provide value for investors in the long-term.

Bears say

Surrozen is currently a developmental-stage biotechnology company with promising drug candidates in its pipeline, however, the stock faces significant risk factors that could hinder its potential success and achievement of peak commercial revenue estimates. These risks include the possibility of failure in development and commercialization of its products, as well as difficulties in securing necessary capital resources. Additionally, the company's current valuation of $44 per share may not be sustainable if these risks are not mitigated.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.